BrainFulness
Treatment for Major Depression and Anxiety - with NO SIDE EFFECTS!
Company Overview
Snapshot
Founded in September 2015 by Prof. Haim Knobler and Abraham Shoshani, BrainFulness operates with 1–10 employees. The company has raised $55K across one funding round and holds patents in Israel, the United States, Germany, and Japan. In December 2015, BrainFulness secured a grant from the Israel Innovation Authority.
Business overview
BrainFulness is a Health Tech & Life Sciences company focused on developing a novel technology for treating brain diseases such as major depression, ADHD, and dementia. The company's core product is a non-invasive technology designed to offer therapeutic benefits without side effects. BrainFulness serves the healthcare market, targeting patients in regions including Japan, Europe, Israel, and the Americas, and operates within the medical devices and mental health sectors.
Log in to access full profile ›Company Intelligence Q&A
- When was BrainFulness founded and by whom?
- BrainFulness was founded in September 2015 by Prof. Haim Knobler and Abraham Shoshani.
- What is BrainFulness's primary focus in the healthcare sector?
- BrainFulness focuses on developing new technology for treating major depression, ADHD, and dementia, emphasizing treatments with no side effects.
- Has BrainFulness secured any grants?
- In December 2015, BrainFulness secured a grant from the Israel Innovation Authority.
- In which countries does BrainFulness hold patents for its technology?
- BrainFulness has registered for patents in Israel, the United States, Germany, and Japan.
- What is the current employee size of BrainFulness?
- BrainFulness currently has 1–10 employees.